Menu Search
Equities

Talphera Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
R5XA:MUN

Talphera Inc

Actions
  • Price (EUR)0.684
  • Today's Change-0.018 / -2.56%
  • Shares traded200.00
  • 1 Year change+14.77%
  • Beta0.5060
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

  • Revenue in USD (TTM)28.00k
  • Net income in USD-12.46m
  • Incorporated2005
  • Employees13.00
  • Location
    Talphera Inc1850 Gateway Drive, Suite 175SAN MATEO 94404United StatesUSA
  • Phone+1 (650) 216-3500
  • Fax+1 (302) 636-5454
  • Websitehttps://talphera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.